SCHEMBL4041485

SCHEMBL4041485

COc1cc(Nc2nc(N)n(-c3ccnc(SC)n3)n2)ccc1OCCCN1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.55
KIT P10721 3/20 0.49
IRAK4 Q9NWZ3 2/20 0.49
AURKA O14965 1/20 0.49
JAK2 O60674 1/20 0.49
BACE1 P56817 3/20 0.47
AXL P30530 5/20 0.46
JAK3 P52333 3/20 0.45
BTK Q06187 3/20 0.45
INSR P06213 1/20 0.45
EHMT2 Q96KQ7 1/20 0.43
EHMT1 Q9H9B1 1/20 0.43
IGF1R P08069 1/20 0.43
ATM Q13315 1/20 0.43
EGFR P00533 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040492 0.91 FLT3 (0.53) FLT3KITIRAK4AURKAJAK2
SCHEMBL4041990 0.86 FLT3 (0.74) FLT3KITIRAK4AURKAJAK2
SCHEMBL4039353 0.83 FLT3 (0.71) FLT3KITIRAK4AURKAJAK2
SCHEMBL4041228 0.82 FLT3 (0.70) FLT3KITIRAK4AURKAJAK2
SCHEMBL12779995 0.80 FLT3 (0.57) FLT3KITIRAK4AURKAJAK2
SCHEMBL12780012 0.80 FLT3 (0.56) FLT3KITIRAK4AURKAJAK2
SCHEMBL12780085 0.79 FLT3 (0.51) FLT3KITIRAK4AURKAJAK2
SCHEMBL12780015 0.78 FLT3 (0.54) FLT3KITIRAK4AURKAJAK2
SCHEMBL4042846 0.78 FLT3 (0.72) FLT3KITIRAK4AURKAJAK2
SCHEMBL12780136 0.78 FLT3 (0.52) FLT3KITIRAK4AURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885KIT 1144/4885IRAK4 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.